Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05742217
Status:
RECRUITING
Last Update Posted:
2024-02-20
First Post:
2023-02-15
Brief Title:
A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma TCR-MM Are Treated in Italian Centers for Blood Related Diseases
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
MUltiple Myeloma Italian ObServational sTudy MUST
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MUST
Brief Summary:
Multiple myeloma MM is a type of cancer of the white blood cells called plasma cells These plasma cells help in fighting infections
TCR-MM is when the cancer does not get treated with the 3 main classes of medicines used to treat this disease
The purpose of this study is to learn about the present clinical practice in Italy and describe the standard of care that will be given to patients with TCR-MM and their treatment costs in around 25 centers who treat patients with blood diseases
Standard of care SoC is the treatment that is accepted as a proper treatment for a certain type of disease and that is widely used by doctors
The study is seeking for participants who are
18 years of age or older
Confirmed to have MM
do not show any response when treated with the 3 main classes of medicines used to treat MM Data of participants who received the TCR treatment between 01 December 2021 and 31 May will be collected
The main data source for the study will be the patient medical record No clinical visits examinations or procedures are required as part of this study
TCR-MM is when the cancer does not get treated with the 3 main classes of medicines used to treat this disease
The purpose of this study is to learn about the present clinical practice in Italy and describe the standard of care that will be given to patients with TCR-MM and their treatment costs in around 25 centers who treat patients with blood diseases
Standard of care SoC is the treatment that is accepted as a proper treatment for a certain type of disease and that is widely used by doctors
The study is seeking for participants who are
18 years of age or older
Confirmed to have MM
do not show any response when treated with the 3 main classes of medicines used to treat MM Data of participants who received the TCR treatment between 01 December 2021 and 31 May will be collected
The main data source for the study will be the patient medical record No clinical visits examinations or procedures are required as part of this study
Detailed Description:
In Italy MM represents 16 percent of all cancers diagnosed in men and 15 percent of those diagnosed in women The 2020 Italian epidemiological data show 5759 new diagnosis of MM Most MM patients relapse or become refractory to various therapeutic approaches and typically cycle through many lines of treatment Survival among patients refractory to newer therapies including PIs IMiDs and anti-CD38 mAbs is very low and measured in months An Italian real life data collection is important to analyse the current therapeutic approaches in TCR patients and the costs incurred by the therapy based on the different treatments
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MUST | OTHER | Alias Study Number | None |